Enveric Biosciences Announces Positive Results from Recently Completed IND-enabling ADMET Studies

Enveric Biosciences Inc. (ENVB) — CAMBRIDGE, Mass., October 21, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced positive results from recently completed IND-enabling in vitro Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) studies for its lead non-hallucinogenic, neuroplastogenic candidate EB-003.

Source: Business Wire — read the full announcement there.

Browse more sector announcements in our press release archive.